EP2072057A1 — Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
Assigned to Merz Pharma GmbH and Co KGaA · Expires 2009-06-24 · 17y expired
What this patent protects
The present invention relates to a Clostridium botulinum neurotoxin for the treatment of spasticity related to a cerebrovascular event or to a cerebral or spinal cord injury, wherein onset of treatment is less than 11 days after the cerebrovascular event or cerebral or spinal c…
USPTO Abstract
The present invention relates to a Clostridium botulinum neurotoxin for the treatment of spasticity related to a cerebrovascular event or to a cerebral or spinal cord injury, wherein onset of treatment is less than 11 days after the cerebrovascular event or cerebral or spinal cord injury. Moreover, the present invention relates to a method of treatment of spasticity related to a cerebrovascular event or spinal cord injury, the method comprising administering to a patient a composition comprising an effective amount of a Clostridium botulinum toxin, wherein (a) the composition comprises: i. the neurotoxic component of the Clostridium botulinum toxin complex, being free of the complexing proteins of the botulinum toxin complex, or ii. the botulinum toxin complex; or iii. mixtures thereof and (b) the composition is administered less than 11 days after the cerebrovascular event; and (c) the composition is administered by injection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.